Ajanta Pharma Partners With Biocon For Semaglutide Supply Across 26 Countries

Ajanta Pharma Ltd announced on December 23, 2025, that it has entered into an in-licensing agreement with Biocon Ltd for Semaglutide, a leading GLP-1 receptor agonist used in diabetes and obesity management. 

Biocon will supply Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive rights in 3 countries across Africa, the Middle East, and Central Asia. This partnership is expected to expand Ajanta’s therapeutic offerings and enhance its global footprint in chronic disease management. Regulatory approvals are anticipated by late 2026 or early 2027, paving the way for commercialization.

Key Highlights

• Ajanta Pharma signs in-licensing agreement with Biocon for Semaglutide
• Biocon to supply Semaglutide for 26 countries, including exclusive rights in 23 markets
• The agreement strengthens Ajanta’s presence in diabetes and obesity treatment segments
• Commercialization expected post regulatory approvals by late 2026 or early 2027
• Partnership reflects growing demand for GLP-1 therapies globally, driven by rising lifestyle-related health challenges

Sources: InvestyWise, Biocon Press Releases, Moneycontrol